<DOC>
	<DOCNO>NCT01597414</DOCNO>
	<brief_summary>Chemotherapy HER2 target agent improve survival significantly metastatic breast cancer . Chemotherapy however associate significant side-effects impact Quality Life functionality old patient . The investigator aim establish HER2 targeted regimen minimal toxicity order delay even avoid use classical chemotherapy compete risk death frail/elderly patient group .</brief_summary>
	<brief_title>Elderly Metastatic Breast Cancer : Pertuzumab-Herceptin v Pertuzumab-Herceptin-Metronomic Chemotherapy , Followed T-DM1</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients histologically proven HER2 positive Newly diagnose recurrent ( surgery ) stage IV disease ( TNM/AJCC v.7 ) . Patients must measurable ( RECIST v. 1.1 ) evaluable disease Performance status ( PS ) 03 ( WHO ) Age ≥ 70 year age , ≥ 60 year old required number dependency Life expectancy 12 week Previous adjuvant chemotherapy/anti HER2 therapy surgery allow , give time interval end previous treatment initiation treatment metastatic disease ≥ 6 month . Up one line antiHER therapy ( trastuzumab lapatinib ) allow combination hormone therapy hormone sensitive metastatic breast cancer . Adequate organ function Before patient randomization , write informed consent must give accord ICH/GCP , national/local regulation . No brain metastasis untreated , symptomatic , require steroid control symptom ; radiation , surgery , therapy control symptom brain metastasis within 2 month prior first study treatment . No prior chemotherapy metastatic disease allow No prior treatment pertuzumab allow No history exposure follow cumulative dos anthracyclines : Doxorubicin liposomal doxorubicin &gt; 360 mg/m2 Epirubicin &gt; 720 mg/m2 Mitoxantrone &gt; 120 mg/m2 Idarubicin &gt; 90 mg/m2 If another anthracycline 1 anthracycline use , cumulative dose must exceed equivalent 360 mg/m2 doxorubicin . No history palliative radiotherapy within 14 day randomization No history malignancy within last 5 year , except carcinoma situ cervix basal cell spinocellular carcinoma skin No current uncontrolled hypertension ( persistent systolic &gt; 180 mmHg and/or diastolic &gt; 100 mmHg ) No LVEF 50 % No history significant cardiac disease define : Symptomatic CHF ( NYHA class IIIV ) Highrisk uncontrolled arrhythmias History myocardial infarction within 6 month prior randomization Clinically significant valvular heart disease No angina pectoris require antiangina treatment No peripheral neuropathy Grade ≥ 3 per NCI CTCAE version 4.0 . No current severe , uncontrolled systemic disease ( e.g. , clinically significant cardiovascular , pulmonary , metabolic disease ; wound heal disorder ; ulcer ; bone fracture , know infection HIV , active hepatitis B and/or hepatitis C virus ) No major surgical procedure significant traumatic injury within 28 day prior randomization anticipation need major surgery course study treatment No history receive investigational treatment within 28 day randomization No history intolerance ( include Grade 34 infusion reaction ) trastuzumab No unwillingness inability comply requirement protocol assessed investigator Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>